Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
Get Alerts ATOS Hot Sheet
Join SI Premium – FREE
SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.
Details of the company's participation are as follows:
- Cantor Fitzgerald Global Healthcare Conference 2023
- Format: Fireside Chat with Chief Executive Officer Steven Quay, M.D., Ph.D.
- Date and Time: Thursday, September 28th at 9:10 A.M. ET
- Location: New York, NY
Interested parties may access the live webcast of the fireside chat by visiting the Investors section of the Atossa website at https://investors.atossatherapeutics.com. The webcast replay will be archived on the Atossa website for 90 days following the conclusion of the event.
About Atossa TherapeuticsAtossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit www.atossatherapeutics.com.
Contact:Eric Van ZantenVP, Investor and Public Relations610-529-6219[email protected]
Source: Atossa Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
- Global Times: How fresh dynamics, fierce competition reshape China's auto market
- L3Harris Celebrates Successful Launch of NASA’s Nancy Grace Roman Space Telescope
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share